CD274 and non-small cell lung carcinoma: Around 10% of PD-L1 negative NSCLC patients respond to targeted immune therapy; a subset of the PD-1 positive but PD-L1 negative cases may serve as potential candidates for immune therapy in clinical trials in search of finding these PD-L1 negative therapy responders.